Antibiotic resistance is a mounting global health concern. The World Health Organization (WHO) reports a significant increase in drug-resistant infections, highlighting the demand for innovative solutions. This challenge is especially alarming in women's health. A study analyzing antimicrobial resistance patterns in vaginal swab samples from 2019 to 2022 shows an increasing resistance among vaginal pathogens, making it more challenging to manage these infections with standard treatments.
COOLOGICS, a clinical-stage medical device company, recognizes this concern. It seeks to help reduce the unnecessary use and overuse of antibiotics in treating common vaginal infections by developing impactful solutions. One of its most promising advancements is Vlisse™, a non-drug treatment that intends to address yeast and bacterial vaginal infections through controlled cooling technology.
